MX366728B - Uso de serlopitant como antagonistas del receptor nk-1 en prurito. - Google Patents

Uso de serlopitant como antagonistas del receptor nk-1 en prurito.

Info

Publication number
MX366728B
MX366728B MX2015017763A MX2015017763A MX366728B MX 366728 B MX366728 B MX 366728B MX 2015017763 A MX2015017763 A MX 2015017763A MX 2015017763 A MX2015017763 A MX 2015017763A MX 366728 B MX366728 B MX 366728B
Authority
MX
Mexico
Prior art keywords
serlopitant
pruritus
receptor antagonist
receptor antagonists
additional
Prior art date
Application number
MX2015017763A
Other languages
English (en)
Spanish (es)
Other versions
MX2015017763A (es
Inventor
W Larrick James
Zhang Xiaoming
F Schnipper Edward
J Perlman Andrew
Original Assignee
Menlo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by Menlo Therapeutics Inc filed Critical Menlo Therapeutics Inc
Publication of MX2015017763A publication Critical patent/MX2015017763A/es
Publication of MX366728B publication Critical patent/MX366728B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015017763A 2013-06-24 2014-06-24 Uso de serlopitant como antagonistas del receptor nk-1 en prurito. MX366728B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Publications (2)

Publication Number Publication Date
MX2015017763A MX2015017763A (es) 2016-06-21
MX366728B true MX366728B (es) 2019-07-22

Family

ID=51230173

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015017763A MX366728B (es) 2013-06-24 2014-06-24 Uso de serlopitant como antagonistas del receptor nk-1 en prurito.
MX2019008643A MX2019008643A (es) 2013-06-24 2015-12-18 Uso de serlopitant como antagonistas del receptor nk-1 en prurito.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019008643A MX2019008643A (es) 2013-06-24 2015-12-18 Uso de serlopitant como antagonistas del receptor nk-1 en prurito.

Country Status (13)

Country Link
EP (1) EP3013336A1 (ko)
JP (2) JP2016523260A (ko)
KR (1) KR20160023692A (ko)
CN (1) CN105473138A (ko)
AU (2) AU2014302694B2 (ko)
BR (1) BR112015031724A2 (ko)
CA (1) CA2915474A1 (ko)
HK (1) HK1223820A1 (ko)
IL (1) IL243189A0 (ko)
MX (2) MX366728B (ko)
PH (2) PH12015502777A1 (ko)
RU (1) RU2666219C2 (ko)
WO (1) WO2014209962A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
JP6741655B2 (ja) 2014-09-19 2020-08-19 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アプレピタントのエマルジョン製剤
KR20230173743A (ko) * 2015-03-04 2023-12-27 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
AU2016391046A1 (en) * 2016-02-01 2018-08-16 Heron Therapeutics, Inc. Emulsion comprising an NK-1 receptor antagonist
KR20190039936A (ko) * 2016-06-29 2019-04-16 멘로 쎄라퓨틱스 인크. 다양한 소양증성 병태를 치료하기 위한 뉴로키닌-1 길항제의 용도
AU2018331267B2 (en) * 2017-09-13 2024-03-07 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2019088926A1 (en) * 2017-11-01 2019-05-09 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
WO2019152232A1 (en) * 2018-01-31 2019-08-08 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
CN115015440A (zh) * 2022-07-08 2022-09-06 江苏杜瑞制药有限公司 一种生物样品中纳呋拉啡的检测方法
CN117503699A (zh) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 阿瑞匹坦口服液制剂及制剂制造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
CN100582093C (zh) * 2004-01-27 2010-01-20 默克公司 氢异二氢吲哚速激肽受体拮抗剂
AR047439A1 (es) * 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
WO2007008564A1 (en) 2005-07-11 2007-01-18 Merck & Co., Inc. Process for making hydroisoindoline tachykinin receptor antagonists
AU2006302562A1 (en) 2005-10-04 2007-04-19 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
US20100209496A1 (en) 2006-09-06 2010-08-19 Eleni Dokou Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
WO2008054690A2 (en) 2006-11-02 2008-05-08 Merck & Co., Inc. Polymorphs of a hydroisoindoline tachykinin receptor antagonist
US20100113469A1 (en) 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (ru) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Гель, обладающий противовоспалительным и противоаллергическим действием

Also Published As

Publication number Publication date
AU2020200259A1 (en) 2020-02-06
JP2019142960A (ja) 2019-08-29
MX2019008643A (es) 2019-09-10
AU2014302694B2 (en) 2019-10-17
RU2666219C2 (ru) 2018-09-06
BR112015031724A2 (pt) 2017-07-25
PH12020500255A1 (en) 2021-02-22
RU2015154037A (ru) 2017-07-28
EP3013336A1 (en) 2016-05-04
PH12015502777A1 (en) 2016-03-21
CA2915474A1 (en) 2014-12-31
HK1223820A1 (zh) 2017-08-11
MX2015017763A (es) 2016-06-21
IL243189A0 (en) 2016-02-29
JP2016523260A (ja) 2016-08-08
KR20160023692A (ko) 2016-03-03
CN105473138A (zh) 2016-04-06
AU2014302694A1 (en) 2016-01-07
WO2014209962A1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
PH12016500642A1 (en) Selective substituted quinoline compounds
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
MX368455B (es) Compuestos de tetrahidropirazolopirimidina.
MX2015002292A (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
SA516370641B1 (ar) مركبات حلقية غير متجانسة وطرق لاستخدامها
MX365242B (es) El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
ZA201506131B (en) Kv1.3 antagonists and methods of use
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2016007947A (es) Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con caracteristicas melancolicas.
MX2016009665A (es) Composiciones y metodos para el tratamiento de la hemorragia cerebral.
ME03086B (me) Antagonisтi kv1.3 i postupci za upotrebu
MX2019009243A (es) Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: NOXELL CORPORATION

FG Grant or registration